Ya Jun Xu
Präsident bei Hongsen Investment Management Ltd.
Profil
Ya Jun Xu was the founder of Shanghai ChemPartner Co., Ltd.
(founded in 2007) where she held the title of Vice President from 2007 to 2014.
She is currently serving as a Board of Director at Abcuro, Inc., a Director at EpimAb Biotherapeutics, Inc., a Director at Aim-Hi Accelerator Fund, Inc., a Senior Advisor at Shangbay Capital Management Co. LLC, the President of ShangPharma Innovation, Inc. (since 2014), an Advisor at HotSpot Therapeutics, Inc., and the President of Hongsen Investment Management Ltd.
Dr. Xu's former job was as a Director at Millennium Pharmaceuticals, Inc. from 2000 to 2006.
Her education includes a doctorate degree from Brandeis University (conferred in 1992), undergraduate and graduate degrees from Beijing University of Chemical Technology (conferred in 1983 and 1986 respectively), and a graduate degree from Harvard T.H.
Chan School of Public Health (conferred in 1995).
Aktive Positionen von Ya Jun Xu
Unternehmen | Position | Beginn |
---|---|---|
Shangbay Capital Management Co. LLC
Shangbay Capital Management Co. LLC Investment ManagersFinance Shangbay Capital Management Co. LLC (Shangbay Capital) is a venture capital firm founded in 2015. The firm is headquartered in Palo Alto, California. | Berater | - |
EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016. | Direktor/Vorstandsmitglied | - |
Aim-Hi Accelerator Fund, Inc.
Aim-Hi Accelerator Fund, Inc. Miscellaneous Commercial ServicesCommercial Services Aim-Hi Accelerator Fund, Inc. is a non-profit company that was born out of the National Foundation for Cancer Research (NFCR). The company is based in Rockville, MD. The company aims to bridge the gap between innovative, early-stage cancer research and successful development of high-impact oncology products. Aim-Hi is a new paradigm to fund translational research designed to focus on startups that have commercial potential at cancer therapeutic discovery. The company was founded by Sujuan Ba, Charlie Weatherspoon, Franklin Cary Salisbury. Sujuan Ba has been the CEO since incorporation. | Direktor/Vorstandsmitglied | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | Präsident | 01.04.2014 |
Abcuro, Inc.
Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | Direktor/Vorstandsmitglied | - |
HotSpot Therapeutics, Inc.
HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | Berater | - |
Hongsen Investment Management Ltd. | Präsident | - |
Ehemalige bekannte Positionen von Ya Jun Xu
Unternehmen | Position | Ende |
---|---|---|
Shanghai ChemPartner Co., Ltd.
Shanghai ChemPartner Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai ChemPartner Co., Ltd. operates as a contract research organization. It provides chemistry, biology, pharmacology, DMPK, process R&D, pre-formulation, and analytical development services to global pharmaceutical and biotech companies. The company was founded in 2003 and is headquartered in Shanghai, China. | Gründer | 02.01.2014 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | 01.12.2006 |
Ausbildung von Ya Jun Xu
Beijing University of Chemical Technology | Graduate Degree |
Brandeis University | Doctorate Degree |
Harvard T.H. Chan School of Public Health | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 9 |
---|---|
Shangbay Capital Management Co. LLC
Shangbay Capital Management Co. LLC Investment ManagersFinance Shangbay Capital Management Co. LLC (Shangbay Capital) is a venture capital firm founded in 2015. The firm is headquartered in Palo Alto, California. | Finance |
EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016. | Health Technology |
Aim-Hi Accelerator Fund, Inc.
Aim-Hi Accelerator Fund, Inc. Miscellaneous Commercial ServicesCommercial Services Aim-Hi Accelerator Fund, Inc. is a non-profit company that was born out of the National Foundation for Cancer Research (NFCR). The company is based in Rockville, MD. The company aims to bridge the gap between innovative, early-stage cancer research and successful development of high-impact oncology products. Aim-Hi is a new paradigm to fund translational research designed to focus on startups that have commercial potential at cancer therapeutic discovery. The company was founded by Sujuan Ba, Charlie Weatherspoon, Franklin Cary Salisbury. Sujuan Ba has been the CEO since incorporation. | Commercial Services |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | Finance |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Abcuro, Inc.
Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | Commercial Services |
HotSpot Therapeutics, Inc.
HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | Health Technology |
Shanghai ChemPartner Co., Ltd.
Shanghai ChemPartner Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai ChemPartner Co., Ltd. operates as a contract research organization. It provides chemistry, biology, pharmacology, DMPK, process R&D, pre-formulation, and analytical development services to global pharmaceutical and biotech companies. The company was founded in 2003 and is headquartered in Shanghai, China. | Commercial Services |
Hongsen Investment Management Ltd. |